The Ras-dependent extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein (MAP) kinase pathway plays a central role in cell proliferation control. In normal cells, sustained activation of ERK1/ERK2 is necessary for G1-to S-phase progression and is associated with induction of positive regulators of the cell cycle and inactivation of antiproliferative genes. In cells expressing activated Ras or Raf mutants, hyperactivation of the ERK1/2 pathway elicits cell cycle arrest by inducing the accumulation of cyclin-dependent kinase inhibitors. In this review, we discuss the mechanisms by which activated ERK1/ERK2 regulate growth and cell cycle progression of mammalian somatic cells. We also highlight the findings obtained from gene disruption studies.
Introduction
The cell division cycle is the sequence of events by which cells faithfully replicate their DNA and then segregate the duplicated chromosomal DNA equally between two daughter cells. An intricate network of regulatory pathways ensures that each cell cycle event is performed correctly and in proper sequence (Morgan, 2007) . The decision of cells to replicate their genetic material and divide is made in G1 and is influenced by extracellular signals (nutrients, mitogens, cytostatic factors, extracellular matrix). Once cells make their decision, they are irreversibly committed to complete the cycle independently of mitogenic factors. One of the key signal transduction pathways responsible for integrating these environmental signals and relaying the information to the cell cycle control system is the Ras-dependent extracellular signal-regulated kinase 1 (ERK1)/2 mitogenactivated protein (MAP) kinase pathway.
MAP kinase pathways are evolutionarily conserved signaling modules by which cells transduce extracellular signals into intracellular responses (reviewed in Lewis et al., 1998; Widmann et al., 1999; Pearson et al., 2001) . The prototypical MAP kinase pathway is the ERK1/2 pathway, which is activated preferentially by mitogenic factors, differentiation stimuli and cytokines. The basic principles that govern the activation of this pathway have been established during the 1990s and are relatively well understood. Binding of ligands to their respective cell surface receptors induces the activation of the small GTPase Ras, which recruits the MAP kinase kinase kinase Raf to the membrane for subsequent activation by phosphorylation. Activated Raf isoforms phosphorylate and activate the MAP kinase kinases MEK1/ MEK2, which in turn activate the effector MAP kinases ERK1 and ERK2 by phosphorylation of the Thr and Tyr residues within their activation loop. ERK1/ERK2, which are expressed ubiquitously in mammalian cells, are multifunctional serine/threonine kinases that phosphorylate a vast array of substrates localized in all cellular compartments (Lewis et al., 1998; Pearson et al., 2001; Yoon and Seger, 2006) . These include protein kinases, signaling effectors, receptors, cytoskeletal proteins and nuclear transcriptional regulators. This review focuses on the importance of the ERK1/2 MAP kinase pathway in cell proliferation control. We discuss our current understanding of the mechanisms by which activated ERK1/ERK2 regulate growth and cell cycle progression of mammalian somatic cells.
Sustained activation of the ERK1/2 MAP kinase pathway is necessary for cell proliferation
The first hint about the involvement of ERK1/ERK2 MAP kinases in cell proliferation control came from the observation that the two kinases are rapidly phosphorylated and activated in response to mitogenic stimulation. Indeed, ERK1 and ERK2 were originally identified as mitogen-stimulated phosphoproteins of 41-45 kDa after separation by one-or two-dimensional gel electrophoresis (Nakamura et al., 1983; Cooper et al., 1984; Kohno, 1985; Kohno and Pouyssegur, 1986) . This pair of tyrosine phosphorylated proteins was later shown to correspond to the activated forms of two MAP-2/myelin basic protein (MBP) kinases characterized previously and referred to as p42 mapk (ERK2) and p44 mapk (ERK1) (Rossomando et al., 1989 (Rossomando et al., , 1991 . Subsequent studies confirmed that ERK1/ERK2 are activated in response to virtually all mitogenic factors in diverse cell types. Detailed kinetic analysis revealed that mitogens induce a biphasic activation of ERK1 and ERK2 in fibroblasts, with a rapid and strong burst of kinase activity peaking at 5-10 min followed by a second wave of lower but sustained activity that persists throughout the G1 phase (Kahan et al., 1992; Meloche et al., 1992; Meloche, 1995) . A close correlation was observed between the ability of extracellular factors to induce sustained ERK1/2 activation and DNA synthesis (Kahan et al., 1992; Meloche et al., 1992) . For example, the potent mitogen thrombin was shown to activate ERK1 with biphasic kinetics in hamster lung fibroblasts. Rapid inactivation of thrombin with the antagonist hirudin or pretreatment of cells with pertussis toxin, both of which abolish late-phase activation while preserving the early peak of activity, resulted in complete inhibition of DNA synthesis. These early observations were confirmed by several laboratories using different cellular models (Cook and McCormick, 1996; Weber et al., 1997b; Talarmin et al., 1999; Jones and Kazlauskas, 2001) , allowing the generalization of the model. In a recent study that systematically analyzed the impact of the duration of ERK1/2 activity, it was concluded that ERK1/2 activation must be sustained until late G1 for successful S-phase entry (Yamamoto et al., 2006) . ERK1/ERK2 are rapidly inactivated at the G1/S transition, and their activity is not required for cells to enter S phase (Meloche, 1995) .
The first demonstration of the direct involvement of ERK1/2 in the mitogenic response was provided by the findings that overexpression of ERK1 catalytically inactive mutants or antisense RNA inhibits the activation of endogenous ERK1/ERK2 and exerts a dominant-negative effect on fibroblast cell proliferation (Pages et al., 1993) . The suppression of cell proliferation by antisense ERK1 was fully reverted by co-transfection of a sense ERK1 construct, confirming the specificity of the effect. Later on, other studies showed that overexpression of interfering mutants of MEK1 (Cowley et al., 1994; Seger et al., 1994) , incubation with ERK2 antisense oligonucleotide (Sale et al., 1995) or expression of active MAP kinase phosphatase 1 (MKP-1/DUSP1) (Sun et al., 1994; Brondello et al., 1995) inhibits the induction of DNA synthesis by serum and activated Ras. Similarly, treatment with synthetic MEK1/2 inhibitors, which prevents activation of ERK1/ERK2, was reported to inhibit the proliferation of various cell types, including fibroblasts, T lymphocytes, smooth muscle cells, hepatocytes and epithelial cell lines (Dudley et al., 1995; Seufferlein et al., 1996; Karpova et al., 1997; DeSilva et al., 1998; Williams et al., 1998; SeboltLeopold et al., 1999; Talarmin et al., 1999) . Conversely, expression of constitutively active forms of MEK1 (Brunet et al., 1994; Cowley et al., 1994; Seger et al., 1994) relaxes growth factor dependency and enhances the rate of cell proliferation.
Although ERK1/2 activation is necessary for G1 progression, it is nonetheless insufficient to drive cells into S phase (Cheng et al., 1998; Treinies et al., 1999; Jones and Kazlauskas, 2001 ). Careful temporal dissection of the signaling events required for cells to move from G0 through G1 and into S phase has revealed that accumulation of phosphatidylinositol-3-OH kinase (PI(3)K) lipid products is important for late G1 progression (Jones and Kazlauskas, 2001) . Some studies have reported that overexpression of activated MEK1 in quiescent fibroblasts is sufficient to cause S-phase entry (Cowley et al., 1994; Gotoh et al., 1999; Treinies et al., 1999) . However, it was later shown that induction of DNA synthesis can be blocked by incubation of cells with the PI(3)K inhibitor LY294002, suggesting that activation of the ERK1/2 pathway induces the synthesis of autocrine growth factors (Treinies et al., 1999) . The addition of insulin to serum-free culture medium (Gotoh et al., 1999) may also lead to confounding results, as insulin is able to substitute for (PI(3)K) lipid products in late G1 (Jones and Kazlauskas, 2001 ).
ERK1/2 signaling regulates cell growth
Cell growth is the process by which cells increase their mass by upregulating the biosynthesis of macromolecules, membranes and organelles. In proliferating cells, cell growth is coordinated with the cell division cycle to ensure that on average each cell division is accompanied by a doubling in mass in order to maintain cell size (Jorgensen and Tyers, 2004) . In animals, cell growth is mainly controlled by extracellular growth factors (Conlon and Raff, 1999) . The first evidence linking ERK1/2 signaling to cell growth control stemmed from the finding that PD98059, a synthetic inhibitor of MEK1/ MEK2, blocks the stimulation of global protein synthesis induced by a variety of growth factors acting through tyrosine kinase receptors or G protein-coupled receptors in vascular smooth muscle cells (Servant et al., 1996) . At the same time, it was reported that treatment of cells with PD98059 drastically reduces insulin-and serum-induced phosphorylation of the translation initiation factor eIF4E (Flynn and Proud, 1996; Morley and McKendrick, 1997) . These initial observations suggested that the ERK1/2 pathway might play a role in translational control. Phosphorylation of eIF4E on Ser 209 is mediated by the MAP kinase-activated protein kinase (MK) family members Mnk1/Mnk2, which are directly phosphorylated and activated by the MAP kinases ERK1/ERK2 and p38a/b in response to growth factors or stress stimuli (Fukunaga and Hunter, 1997; Waskiewicz et al., 1997 Waskiewicz et al., , 1999 Ueda et al., 2004) . The functional impact of eIF4E phosphorylation is not clear and has been a subject of debate (Scheper and Proud, 2002) . The current view is that phosphorylation of eIF4E does not lead to a global increase in mRNA translation but rather enhances translation of specific mRNAs with extensive 5 0 UTR structure (Dever, 2002; Mamane et al., 2004) . In agreement with this idea, no change in global protein synthesis was observed in Mnk1/Mnk2-deficient embryonic fibroblasts, despite complete elimination of eIF4E phosphorylation (Ueda et al., 2004) . So why does inhibition of ERK1/2 activity has such a profound effect on general protein synthesis (Servant et al., 1996) ? One mechanism by which ERK1/ ERK2 may stimulate global mRNA translation is through enhancement of mammalian target of rapamycin (mTOR) signaling. mTOR is a master growth regulator that integrates signals from growth factors, nutrients and cellular energy status to modulate ribosome biogenesis and translation initiation (see Fingar and Blenis, 2004; Hay and Sonenberg, 2004; Wullschleger et al., 2006 for reviews) . mTOR activity is negatively regulated by the tuberous sclerosis complex 1 (TSC1)/TSC2 heterodimer, which acts as a GTPase activating protein (GAP) for the small GTPase Rheb (Manning and Cantley, 2003; Corradetti and Guan, 2006) . Rheb binds directly to the mTOR complex 1 (mTORC1) and stimulates mTOR kinase activity in a GTP-dependent manner. Two groups recently reported that activation of the ERK1/2 pathway functionally inactivates the TSC1/TSC2 complex, as a result of the phosphorylation of TSC2 (Roux et al., 2004; Ma et al., 2005) . One study showed that the serine/threonine kinase RSK1, a downstream substrate of ERK1/ ERK2, phosphorylates TSC2 in the conserved Cterminus of the protein (Ser 1798) to impair its antagonistic action on mTOR signaling (Roux et al., 2004) . The other study proposed that ERK1/ERK2 directly phosphorylate TSC2 on Ser 664 and inhibit its function by disrupting TSC1/TSC2 complex formation (Ma et al., 2005) . Thus, the ERK1/2 and PI(3)K pathways cooperate to activate mTOR and promote cell growth.
Another mechanism by which ERK1/ERK2 may impact on global protein synthesis is through direct regulation of ribosomal gene transcription. Activation of the ERK1/2 pathway by growth factors or conditionally active Raf-1 induces an immediate increase in ribosomal RNA transcription, whereas inactivation of the pathway by MEK1/2 inhibitors suppresses basal and stimulated ribosomal transcription (Stefanovsky et al., 2001) . ERK2 was found to phosphorylate directly the RNA polymerase I (Pol I) activator upstream binding factor (UBF) on two conserved threonine residues located in HMG boxes 1 and 2. Mutation of the two phosphorylation sites almost completely abolished the ability of UBF to activate Pol I transcription. ERK1/ ERK2 are also predicted to regulate the synthesis of ribosomal RNA and other ribosomal components indirectly via activation of mTOR signaling (Mayer and Grummt, 2006) and stabilization of c-Myc (see below).
In addition to proteins, cell growth is associated with the upregulation of de novo pyrimidine biosynthesis to meet the increased demand in nucleotides (Evans and Guy, 2004) . Pyrimidine nucleotides serve as essential precursors for the synthesis of RNA and DNA, phospholipids, UDP-sugars and glycogen. The ratelimiting step in the pyrimidine pathway is catalysed by the carbamoyl-phosphate synthetase (CPSase) enzyme, which is part of the large multifunctional protein CAD (Evans and Guy, 2004) . Mitogenic stimulation of cells induces the phosphorylation of CAD and allosterically activates the CPSase domain by an MEK1/2-dependent mechanism (Graves et al., 2000) . ERK2 directly phosphorylates CAD on Thr 456 in vitro, and alanine substitution of this residue abolishes the allosteric regulation of the enzyme. Furthermore, epidermal growth factor-stimulated synthesis of UTP is blocked by incubation with PD98059, consistent with a role of the ERK1/2 pathway in pyrimidine biosynthesis.
ERK1/2 signaling promotes G1 progression by multiple mechanisms
G1-to S-phase progression: a brief overview
The regulation of G1-to S-phase transition is governed by the concerted action of cyclin-dependent kinases (Cdks) and their regulatory cyclin subunits (reviewed in Sherr, 2000; Malumbres and Barbacid, 2001) . In response to mitogenic factors, D-type cyclins progressively accumulate during G1 phase and assemble with their catalytic partners Cdk4 and Cdk6. The activity of Cdk4/6 increases as cells approach the G1/S boundary, and persist through the first and subsequent cycles as long as mitogens are present. A major function of cyclin D-dependent kinases is to phosphorylate members of the retinoblastoma (Rb) family of proteins. Rb phosphorylation disrupts its association with bound E2F family members, allowing the coordinated transcription of genes required for DNA replication (Weinberg, 1995; Harbour and Dean, 2000; Bracken et al., 2004) . Among the E2F-regulated genes are Cyclin E, Cyclin A2 and Emi1, which are key effectors of the G1/S transition in normal cells (Hsu et al., 2002; Cobrinik, 2005) . Cyclin E associates with Cdk2 to enforce Rb phosphorylation and complete its inactivation. A second non-catalytic function of cyclin D-Cdk4/6 complexes is to sequestrate the Cdk inhibitors p27 Kip1 (p27) and p21 Cip1 (p21) (Geng et al., 2001; Tong and Pollard, 2001 ). The binding of p21/p27 to cyclin D-Cdk4/6 stabilizes the complex (LaBaer et al., 1997; Cheng et al., 1999) and relieves cyclin E-Cdk2 from Cdk inhibitor constraint, thereby facilitating activation of cyclin E-Cdk2 later in G1 phase. Once active, Cdk2 also triggers the degradation of p27 through the SCF Skp2 ubiquitin ligase (Cardozo and Pagano, 2004) . Finally, Cdk2 phosphorylates and inactivates the anaphase-promoting complex (APC)-activating subunit Cdh1, which targets a number of S-phase-promoting factors for degradation (Peters, 2002; Ang and Harper, 2004) . The inactivation of Rbfamily proteins, Cdk inhibitors and Cdh1 creates positive feedback loops that reduce the cell's dependency on mitogens and contribute to the irreversibility of S-phase entry.
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Induction of D-type cyclins and assembly of cyclin D-Cdk4 complexes Various mechanisms have been proposed to explain how the ERK1/2 MAP kinase pathway regulates G1-phase progression, although a complete picture is yet to emerge. One key target of the pathway is D-type cyclins. Early studies showed that expression of activated Ras is sufficient to induce the accumulation of cyclin D1 in different cell types (Filmus et al., 1994; Albanese et al., 1995; Liu et al., 1995; Arber et al., 1996; Winston et al., 1996) . Working downstream of Ras, activation of the ERK1/2 pathway was found to be both necessary and sufficient for transcriptional induction of the Cyclin D1 gene (Albanese et al., 1995; Lavoie et al., 1996) . As for entry into S phase, sustained activation of ERK1/ERK2 is required for the continued expression of cyclin D1 in G1 phase (Weber et al., 1997b; Balmanno and Cook, 1999; Roovers et al., 1999) . In fibroblasts, sustained ERK1/2 activity and the associated expression of cyclin D1 depend on the synergistic action of mitogenic factors and cell adhesion to the extracellular matrix (Roovers et al., 1999) . Overexpression of a constitutively active mutant of MEK1 is sufficient to overcome the adhesion requirement for expression of cyclin D1. The precise mechanism and transcriptional regulatory elements that connect ERK1/2 signaling to Cyclin D1 transcription remain to be fully defined. The Cyclin D1 promoter contains a functional AP-1 binding site (Herber et al., 1994; Albanese et al., 1995) and one probable mechanism by which the ERK1/2 pathway impinges on Cyclin D1 transcription is by inducing the expression of AP-1 components. Activation of ERK1/ERK2 by mitogens or conditionally active Raf-1 and MEK1 leads to the elevated expression of individual Fos and Jun family proteins (Hill and Treisman, 1995; Whitmarsh and Davis, 1996; Balmanno and Cook, 1999; Cook et al., 1999; Treinies et al., 1999) . Notably, the repertoire of Fos and Jun proteins expressed in G1 is determined by the duration of ERK1/2 activation (Balmanno and Cook, 1999; Cook et al., 1999) . Specifically, sustained ERK1/2 signaling is required for the induced expression of Fra-1, Fra-2, c-Jun and JunB. Recent findings have provided a molecular explanation for how immediateearly gene products sense the duration of the ERK1/2 signal in fibroblasts (Murphy et al., 2002 (Murphy et al., , 2004 . Many of these gene products including AP-1 family proteins contain functional docking site for ERK, FXFP (DEF) domains. Sustained activation of ERK1/ERK2 induces the phosphorylation of AP-1 proteins at C-terminal residues, resulting in their stabilization and exposure of the DEF domain to prime additional phosphorylation events to further stabilize and activate the proteins. Thus, a strong correlation exists between sustained ERK1/2 activity, AP-1 protein expression and accumulation of cyclin D1 in G1 phase. ERK1/2 signaling also regulates Cyclin D1 transcription through phosphorylation and inactivation of Tob (Maekawa et al., 2002; Suzuki et al., 2002) . Tob is a member of an emerging family of antiproliferative genes, which acts as a transcriptional co-repressor and negatively regulates Cyclin D1 transcription by recruiting histone deacetylase activity to the promoter (Yoshida et al., 2003) . Stimulation with mitogens induces the rapid phosphorylation of Tob by ERK1/ERK2 on three serine residues, canceling the ability of Tob to suppress cyclin D1 expression by a mechanism that remains to be established (Suzuki et al., 2002) .
The ERK1/2 pathway may also control the expression of cyclin D1 at the post-transcriptional level. An important fraction of cellular eIF4E is found within the nucleus, where it associates with nuclear bodies (reviewed in Strudwick and Borden, 2002) . In this compartment, eIF4E functions to promote the nucleo-cytoplasmic export of a subset of growth-associated mRNAs including cyclin D1 (Rousseau et al., 1996; Lai and Borden, 2000; Topisirovic et al., 2002 ) by a mechanism involving an 100-nucleotide sequence in the 3 0 UTR of cyclin D1 mRNA (Culjkovic et al., 2005) . Mutation of Ser 209 or treatment with the synthetic inhibitor of Mnk1/Mnk2 CGP57380 markedly reduced the nuclear export of cyclin D1 mRNA by eIF4E, demonstrating the importance of phosphorylation in this process (Topisirovic et al., 2004) . Incubation with CGP57380 also decreased cyclin D1 protein levels. On the other hand, overexpression of eIF4E had no significant effect on the polysomal distribution of cyclin D1 mRNA (Rosenwald et al., 1995; Rousseau et al., 1996) . These findings suggest a role for the ERK1/2 pathway in the post-transcriptional regulation of cyclin D1 mRNA transport.
Although ERK1/2 signaling has been mainly associated with the induction of cyclin D1, there are a few reports implicating this pathway in the regulation of cyclin D2 (Dey et al., 2000; Piatelli et al., 2002) and cyclin D3 (Tetsu and McCormick, 2003) expression. The generality of these observations and the molecular mechanisms involved remain to be investigated.
Expression of activated MEK1 not only drives the accumulation of D-type cyclins but also facilitates the assembly of cyclin D1-Cdk4 complexes in fibroblasts (Cheng et al., 1998) . This effect might be mediated by downstream phosphorylation of the chaperone Hsc70, which stabilizes newly synthesized cyclin D1 and helps assemble active cyclin D1-Cdk4 holoenzymes (Diehl et al., 2003) . Activation of MEK1 appears to be sufficient to trigger the association of cyclin D1 with Hsc70 (Diehl et al., 2003) .
Stabilization of c-Myc c-Myc is a member of the Myc family of transcription factors that plays a central role in regulating cell growth, cell cycle progression and apoptosis (reviewed in Pelengaris et al., 2002) . c-Myc heterodimerizes with its obligate partner Max to activate or repress transcription of a vast array of target genes (Zeller et al., 2003; Adhikary and Eilers, 2005) . Among the best-defined c-Myc targets that function directly in cell cycle control are cyclin D2 (Bouchard et al., 1999; Coller et al., 2000) , Cdk4 (Hermeking et al., 2000) , p21 (Claassen and Hann, 2000; Coller et al., 2000) and Cdc25A (Galaktionov et al., 1996; Zeller et al., 2003) . In addition, c-Myc also impacts profoundly on cell growth by activating genes ERK1/2 MAP kinases in cell cycle control S Meloche and J Pouysségur encoding ribosomal proteins and translation factors (Adhikary and Eilers, 2005) , and by stimulating transcription of ribosomal RNA genes by Pol I (Arabi et al., 2005; Grandori et al., 2005) . Activation of ERK1/ ERK2 markedly enhances c-Myc protein stability as a result of direct phosphorylation of Ser 62 (Sears et al., 2000) . c-Myc contains a DEF domain that is required for the full phosphorylation of Ser 62 in response to growth factors (Murphy et al., 2004) . It is noteworthy that ERK1/2 signaling and induction of c-Myc are both necessary to drive cells from G0 to late G1 phase (Jones and Kazlauskas, 2001 ).
Regulation of p21 and p27 expression Stimulation of cells with mitogenic factors induces a transient accumulation of the Cdk inhibitor p21 in early G1 phase by a p53-independent mechanism Michieli et al., 1994; Noda et al., 1994; Sheikh et al., 1994; Macleod et al., 1995) . This induction of p21 is dependent on ERK1/2 signaling and is exerted, at least in part, at the level of transcription (Liu et al., 1996; Zezula et al., 1997) . In contrast to the induction of cyclin D1, a transient activation of ERK1/ERK2 is sufficient to induce the expression of p21 . The transient accumulation of p21 likely contributes to the stabilization of cyclin D-Cdk4 complexes in G1 (LaBaer et al., 1997; Cheng et al., 1999; Bagui et al., 2003) . Thus the ERK1/2 pathway may assist in both the assembly and stabilization of cyclin D1-Cdk4/6 complexes. The Cdk inhibitor p27 acts as a primary negative regulator of cell proliferation in a variety of cell types (Nakayama and Nakayama, 1998) . The levels of p27 are high in quiescent cells and decline in response to mitogenic factor stimulation. Several studies have suggested that the Ras-ERK1/2 signaling pathway is involved in the mitogen-induced downregulation of p27 (Kawada et al., 1997; Kerkhoff and Rapp, 1997; Woods et al., 1997; Greulich and Erikson, 1998; Rivard et al., 1999; Treinies et al., 1999; Lenferink et al., 2000; Yang et al., 2000; Delmas et al., 2001; Mirza et al., 2004; Gysin et al., 2005; Sakakibara et al., 2005) . In contrast, other studies failed to document any significant change in p27 levels following inhibition of ERK1/2 signaling by synthetic MEK1/2 inhibitors or dominant-negative ERK2, or after conditional activation of the pathway by activated Raf-1 or MEK1 (Sewing et al., 1997; Takuwa and Takuwa, 1997; Weber et al., 1997a; Cheng et al., 1998; Ladha et al., 1998; Chen et al., 1999; Tetsu and McCormick, 2003) . It was even reported that activated Raf-1 markedly increases p27 expression in small cell lung cancer cell lines (Ravi et al., 1998) . These contradictory observations are difficult to reconcile with a direct and general role of the ERK1/2 pathway in the regulation of p27 by mitogenic factors. It cannot be excluded, however, that this signaling pathway contributes to p27 inactivation in specific cell types or contexts. It is also unclear whether the involvement of ERK1/ ERK2 is direct and if such regulation occurs in normal cells. One of the key mechanisms that regulates p27 abundance is proteolysis by the ubiquitin-proteasome pathway (Pagano et al., 1995) . p27 is phosphorylated on Thr 187 by cyclin E-Cdk2 in late G1 (Sheaff et al., 1997; Vlach et al., 1997) and is then recognized and targeted for ubiquitination by the SCF Skp2 E3 ligase in complex with the cofactor Cks1 (Carrano et al., 1999; Sutterluty et al., 1999; Tsvetkov et al., 1999; Ganoth et al., 2001; Spruck et al., 2001) . The degradation of p27 at the G1/S transition depends on the accumulation of cyclin E and concomitant activation of Cdk2, events that are conditional on earlier activation of cyclin D-Cdk4/6 complexes by the ERK1/2 pathway. However, there is evidence that ERK1/2 signaling can trigger downregulation of p27 expression by a Cdk2-and Skp2-independent mechanism (Delmas et al., 2001; Mirza et al., 2004) . Activation of the ERK1/2 pathway may also contribute indirectly to p27 regulation through the synthesis of autocrine growth factors.
Downregulation of antiproliferative genes
In addition to upregulating proliferation-associated genes, activation of the ERK1/2 pathway also leads to downregulation of antiproliferative genes. A recent gene profiling analysis has identified a set of 173 genes that are downregulated by an ERK1/2-dependent mechanism during G1-phase progression (Yamamoto et al., 2006) . Importantly, overexpression experiments revealed that some of these genes clearly have the ability to inhibit fibroblast growth factor-stimulated DNA synthesis. The list of genes includes Tob1, Ddit3 and JunD, all of which have been associated with the inhibition of cell proliferation. Continuous activation of ERK1/ERK2 throughout G1 is required to maintain decreased expression levels of antiproliferative genes, identifying another mechanism that link the duration of ERK1/2 signaling to the progression from G1 to S phase.
Is ERK1/2 signaling important for G2/M progression and mitosis of somatic cells?
The ERK1/2 signaling pathway has also been implicated in the regulation of the G2/M transition and mitosis in somatic cells. However, the evidence in support of such a role has been controversial. Although some studies have reported that ERK1/ERK2 are phosphorylated/activated during G2/M (Tamemoto et al., 1992; Edelmann et al., 1996; Wright et al., 1999; Roberts et al., 2002) , others concluded that the kinases are inactivated in mitosis (Takenaka et al., 1998; Gomez-Cambronero, 1999; Hayne et al., 2000; Harding et al., 2003) . These results should, however, be interpreted with caution: first, in long-term cellular synchronization studies, the synchrony of cells is not sufficient to measure accurately the level of activation of ERK1/ERK2 in each stage of the cell cycle; second, the use of microtubule-disrupting agents to isolate mitotic cells does not reflect normal progression into M phase. Immunofluorescence studies with phospho-specific antibodies also suggested that ERK1/ERK2 and MEK1/MEK2 are active in mitosis and localized at kinetochores, spindle poles and midbody ERK1/2 MAP kinases in cell cycle control S Meloche and J Pouysségur Zecevic et al., 1998; Willard and Crouch, 2001; Liu et al., 2004) . However, more recent studies have shown that phospho-specific antibodies to MEK1/MEK2 strongly cross-react with phosphorylated nucleophosmin, a multifunctional nuclear phosphoprotein involved in centrosome duplication (Cha et al., 2004; Hayne et al., 2004) . Also, the labeling of centromeric regions, centrosomes and midbodies observed with the phospho-ERK1/2 antibody could not be blocked by pretreatment with the MEK1/2 inhibitor U0126, although the drug completely suppressed the weak phospho-ERK1/2 signal observed by immunoblot analysis in mitotic cells (Shinohara et al., 2006) . Thus, there is no conclusive evidence that ERK1/ERK2 MAP kinases are active in mitosis.
Inhibition of the ERK1/2 pathway by pharmacological or genetic approaches was reported to delay the G2/ M progression of cells (Wright et al., 1999; Hayne et al., 2000; Roberts et al., 2002; Liu et al., 2004; Knauf et al., 2006) . However, the interpretation of these studies is complicated by the fact that MEK1/MEK2 inhibitors were added for long periods of time and it is therefore difficult to distinguish whether the delay in mitosis entry results from a direct effect of ERK1/ERK2 in late G2 or from an indirect consequence of earlier cell cycle defects. The role of ERK1/2 signaling in the G2/M transition and mitotic progression was revisited in a recent study using time-lapse video microscopy in live cells to precisely monitor the timing of these transitions (Shinohara et al., 2006) . The inhibitors of MEK1/ MEK2 were added to cell cultures 15 min before recording the observations, which is enough to suppress ERK1/ERK2 activity completely. These studies revealed that ERK1/2 signaling is not required in late G2 for the timely entry into or exit from mitosis in both normal and transformed cells. No evidence for defect in centrosome duplication, bipolar spindle assembly, chromosome segregation or cytokinesis was observed when the ERK1/2 pathway was inactivated during late G2. Using CENP-F staining as a marker for G2 progression, it was found that inhibition of ERK1/ERK2 activity causes a transient delay in early-mid-G2, which translates into a retardation of the mitotic index. However, this delay is transient, and after 4-5 h the cells resume cycling into mitosis. The molecular basis of this requirement in early-to mid-G2 is not known. Together, these observations suggest that ERK1/2 signaling exerts a modulatory role in early G2 for timely progression towards mitosis, but is dispensable after this time for mitosis to proceed. The ERK1/2 pathway may also be involved in the G2 DNA damage checkpoint response (Abbott and Holt, 1999; Tang et al., 2002; Yan et al., 2005) .
Too strong ERK1/2 signaling leads to reversible or permanent cell cycle arrest Not only the duration, but also the magnitude of the ERK1/2 signal plays a key role in determining the final cellular outcome of this pathway (reviewed in Roovers and Assoian, 2000; Ebisuya et al., 2005) . Several studies have shown that strong activation of ERK1/ERK2 by conditionally active Ras or Raf causes cell cycle arrest in established cell lines by inducing the expression of the Cdk inhibitor p21 (Pumiglia and Decker, 1997; Sewing et al., 1997; Woods et al., 1997; Kerkhoff and Rapp, 1998; Tombes et al., 1998) . The persistent accumulation of p21 has been associated with inhibition of Cdk4 and Cdk2 enzymatic activities and the resulting arrest in G1. Titration of activated Raf expression levels demonstrated that cells display bell-shaped dose-response curves; low Raf signal promotes cell cycle progression and S-phase entry, whereas high Raf activity inhibits DNA synthesis (Sewing et al., 1997; Woods et al., 1997) . These studies have led to a model that integrates the amplitude and duration of ERK1/2 activity with cell cycle progression (Roovers and Assoian, 2000) . A robust early phase of ERK1/2 signaling followed by a moderate sustained phase leads to transient induction of p21 and accumulation of cyclin D1, allowing G1 progression. However, a robust and prolonged activation of ERK1/ERK2 causes G1 arrest due to long-term p21 induction and Cdk2 inhibition. It should be noted that high-intensity ERK1/2 signaling induces the expression of the Cdk inhibitors p16
Ink4a and p15 Ink4b in certain cell lines, which can also contribute to cell cycle arrest (Malumbres et al., 2000; Han et al., 2005) .
The induction of cell cycle arrest by hyperactivation of the ERK1/2 pathway is not restricted to cell lines but is also observed in non-immortalized primary cells. Expression of activated forms of Ras, Raf or MEK1 was shown to elicit cell cycle arrest in primary fibroblasts, Schwann cells, hepatocytes, T lymphocytes, keratinocytes, astrocytes and epithelial intestinal cells Serrano et al., 1997; Lin et al., 1998; Tombes et al., 1998; Zhu et al., 1998; Chen et al., 1999; Fanton et al., 2001; Roper et al., 2001; Boucher et al., 2004) . Notably, the proliferation arrest observed in primary fibroblasts, astrocytes and epithelial intestinal cells is permanent and phenotypically related to cellular senescence (Serrano et al., 1997; Lin et al., 1998; Zhu et al., 1998; Chen et al., 1999; Fanton et al., 2001; Boucher et al., 2004) . ERK1/2-induced cell cycle arrest of normal cells is generally associated with upregulation of p53, p21 and p16
Ink4a
, although the repertoire of Cdk inhibitors solicited varies depending on cell type and context. Interestingly, certain cells use two distinct and redundant cell cycle inhibitory pathways. In normal human astrocytes with an intact p16 Ink4a /Rb pathway, activated Raf-1 induces an irreversible senescence-like proliferation arrest associated with upregulation of p16 Ink4a expression (Fanton et al., 2001) . However, when the p16 Ink4a /Rb pathway is disrupted by expression of E7 oncoprotein in normal astrocytes or by genetic inactivation in high-grade glioma cell lines, Raf-1 activation leads to reversible cell cycle arrest as a consequence of p21 induction. It has been proposed that induction of Cdk inhibitors in response to abnormal mitogenic signaling and the resulting cell cycle arrest is a crucial mechanism for protection against cancer development ERK1/2 MAP kinases in cell cycle control S Meloche and J Pouysségur (Serrano et al., 1997; Lloyd, 1998 ) has provided strong support for the physiological importance of this tumor suppression mechanism (Collado et al., 2005; Michaloglou et al., 2005) .
Role of ERK1 and ERK2: lessons from knockout mice
Further demonstration of the critical role of ERK1/ ERK2 MAP kinases in the regulation of cell proliferation was provided by gene disruption experiments.
Analysis of Erk1
À/À mice revealed that ERK1 is not essential for embryonic development and for normal growth or fertility (Pages et al., 1999) . No difference in proliferation rate, mitogenic factor requirement, magnitude of DNA synthesis stimulation or timing of re-entry into the cell cycle from G0 could be documented in ERK1-deficient embryonic fibroblasts as compared to wild-type cells. While the expression level of ERK2 was unchanged in ERK1 À/À fibroblasts, the mitogen-stimulated phosphorylation of ERK2 was more sustained in these cells, suggesting a possible compensatory effect. On the other hand, loss of ERK1 resulted in a marked inhibition of DNA synthesis in thymocytes stimulated by T-cell receptor crosslinking, despite the expression and activation of ERK2. Disruption of the Erk2 gene leads to early embryonic lethality (Hatano et al., 2003; Saba-El-Leil et al., 2003; Yao et al., 2003) . Erk2 À/À mice die in utero around day e7.5 likely owing to a defect in trophoblast development. Analysis of chimeric embryos demonstrated that Erk2 functions cell autonomously in extra-embryonic lineages for the development of the ectoplacental cone and extra-embryonic ectoderm (Saba-El-Leil et al., 2003) . No proliferation of polar trophectoderm cells is observed in Erk2 homozygous mutants. Given the primordial role of fibroblast growth factor 4 (FGF4) in promoting the proliferation of trophectoderm cells (Rossant and Cross, 2001 ) and the importance of ERK1/ERK2 MAP kinases in transducing signals from growth factor receptors, it has been suggested that ERK2 functions downstream of FGF receptor 2 and is required to transduce the mitogenic signal of FGF4 in polar trophectoderm cells (SabaEl-Leil et al., 2003) . Interestingly, ERK1 is widely expressed in early mouse embryos. The lack of compensation of ERK2 deficiency by ERK1 raises the intriguing possibility that ERK2 may play a specific role in the developing embryo. In a recent study, the role of ERK1 and ERK2 in T-cell development was analysed by crossing Erk1 À/À mice to mice bearing a conditional allele of Erk2 (Fischer et al., 2005) . No difference in thymic subpopulations was observed in mice deficient only for ERK1. However, conditional deletion of Erk2 in the T-cell lineage resulted in a substantial increase in the number of DN3 thymocytes, suggesting a partial block in the maturation from DN3 to DN4 stage.
A similar phenotype was observed in mice with deletion of both Erk1 and Erk2 genes, although the penetrance of the defect was highly variable; some mice had very few DN4 cells, whereas others were only moderately affected. Immunoblot analysis of ERK2 levels in DN3 and DN4 populations revealed that ERK2 expression was reduced but still detectable at the DN4 stage, indicating that some cells have escaped Erk2 excision. These results suggest that ERK2 signaling is required for proliferation of thymocytes through the DN4 stage of development (Fischer et al., 2005) .
One important question that remains unanswered is whether ERK1 and ERK2 isoforms have unique roles in cell proliferation control or if they are used interchangeably to reach a necessary threshold of ERK activity that is specific to each cell type. ERK1 and ERK2 display 83% amino-acid identity overall and it is generally assumed, although not rigorously tested, that the two kinases phosphorylate common substrates. Interestingly, a global analysis of protein phosphorylation in yeast using proteome chips has revealed that closely related kinases can recognize distinct sets of substrates (Ptacek et al., 2005) . For example, the yeast protein kinase A homologues Tpk1, Tpk2 and Tpk3, which are highly related in sequence (from 67 to 84% amino-acid identity between isoforms), have unique substrate specificity and share only a few substrates. Analysis of mice bearing inactivating mutations of Erk1 and Erk2 genes suggests that ERK1 and ERK2 have both overlapping and unique cellular functions. The phenotype of Erk2 À/À mice observed in trophoblast cells and thymocytes cannot be simply explained by the lack of redundant expression of ERK1 (Saba-El-Leil et al., 2003; Fischer et al., 2005) . In a mouse model of myocardial infarction, loss of a single Erk2 allele was shown to increase cardiac cell death, providing genetic evidence for a role of ERK1/2 signaling in cell survival (Lips et al., 2004) . Strikingly, complete inactivation of Erk1 did not enhance infarction susceptibility despite similar impact on total cardiac ERK1/2 enzymatic activity. On the other hand, ERK1 deficiency was found to decrease the incidence and progression of skin papillomas in a two-stage mouse skin carcinogenesis model using 7,12-dimethylbenz(a)anthracene as initiator and 12-O-tetra-decanoyl-phorbol-13-acetate (TPA) as promoter (Bourcier et al., 2006) . Keratinocytes isolated from Erk1 À/À mice showed a reduced proliferative response to mitogens as compared to wild-type cells.
Intriguingly, it has been recently suggested that ERK1 acts as a negative regulator of cell proliferation in fibroblasts by restraining ERK2-dependent signaling (Vantaggiato et al., 2006) . This idea of a competition model is based on the observations that inactivation of ERK1 by either genetic disruption or RNAi silencing increases the proliferation rate of fibroblasts, whereas knockdown of ERK2 expression dramatically inhibits cell proliferation. Reciprocally, overexpression of ERK1, but not ERK2, was found to attenuate the ability of activated Ras to transform NIH 3T3 cells (Vantaggiato et al., 2006) . However, these findings are discrepant with observations made by others. No ERK1/2 MAP kinases in cell cycle control S Meloche and J Pouysségur difference in the proliferation rate of ERK1-deficient embryonic fibroblasts was observed in a previous study (Pages et al., 1999) , whereas RNAi silencing of ERK1 expression inhibited the proliferation of HeLa cells to the same extent as ERK2 silencing (Liu et al., 2004) . Physiologically, Erk1 À/À mice do not grow faster than their littermate controls in three different genetic backgrounds (Pages et al., 1999; S Meloche, unpublished observations) . Additional work using unbiased genetic approaches will be required to clarify the individual roles of ERK1 and ERK2.
Concluding remarks
The ERK1/2 MAP kinase pathway has emerged as a central regulator of cell proliferation by controlling both cell growth and cell cycle progression. Major advances have been made over the last 10 years in identifying the targets of this signaling pathway that are linked to the cell-cycle control machinery. The importance of the amplitude and duration of the ERK1/2 signal in normal cell proliferation and oncogene-induced senescence has been highlighted in a series of elegant studies. However, several important issues still remain unresolved. The individual contribution of ERK1 and ERK2 isoforms to these cellular processes has not been adequately addressed. Knock-in gene replacement strategies with complementation studies and chemical genetic approaches should help to determine unequivocally whether ERK1 and ERK2 have evolved specific cellular functions. The systematic characterization of the physiological substrates of ERK1 and ERK2 will be critical to understanding how these kinases work at the cellular level. Historically, phosphorylation has been studied at the level of single molecules, but new proteomic strategies now allow the global characterization of the cell phosphoproteome. The Ras-ERK1/2 MAP kinase pathway is viewed as an attractive signaling pathway for the development of targeted cancer therapies (SeboltLeopold and Herrera, 2004) . A better understanding of this pathway is likely to have enormous repercussions on drug development.
